Single-Blind, Placebo Phase-in Trial of Two Escalating Doses of Selegiline in the Chronic Fatigue Syndrome

Natelson, Benjamin H.; Cheu, J; Hill, Nancy; Bergen, Michael T.; Korn, Leo; Denny, Thomas N.; Dahl, Kristina

doi:10.1159/000026494

Cited by 47 publications

(11 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A mix of validated tools for different dimensions or domains is needed to take into consideration the wide and pervasive impact of this ill-* References 22,26,[29][30][31]33,35,37,43,45,51. ness on many domains. A comprehensive review of outcome measures currently used would be the first step in this process.…”

Section: Commentmentioning

confidence: 99%

Interventions for the Treatment and Management of Chronic Fatigue Syndrome

Whiting¹,

Bagnall²,

Sowden³

et al. 2001

JAMA

448

277

View full text Add to dashboard Cite

Overall, the interventions demonstrated mixed results in terms of effectiveness. All conclusions about effectiveness should be considered together with the methodological inadequacies of the studies. Interventions which have shown promising results include cognitive behavioral therapy and graded exercise therapy. Further research into these and other treatments is required using standardized outcome measures.

show abstract

Section: Commentmentioning

confidence: 99%

Interventions for the Treatment and Management of Chronic Fatigue Syndrome

Whiting¹,

Bagnall²,

Sowden³

et al. 2001

JAMA

448

277

View full text Add to dashboard Cite

show abstract

“…The MAOIs phenelzine [69] and selegiline [70] also demonstrated a therapeutic effect in CFS. However, wellknow adverse events such as hypertensive crisis attenuated the interest in these medications.…”

Section: Monoamine Oxidase Inhibitorsmentioning

confidence: 97%

Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants

Pae

Marks

Patkar

et al. 2009

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Chronic fatigue syndrome (CFS) is characterized by chronic, medically unexplained fatigue associated with effort- and stress-intolerance, widespread pain, and impairment in sleep and concentration. Although this constellation of symptoms is highly prevalent in clinical practice, the pathophysiological mechanisms underlying CFS are poorly understood. Current evidence indicates similarities in symptomatology, and possibly etiology and pathogenesis, between CFS and depression. Additionally, there is significant overlap between CFS and the syndrome of fibromyalgia for which antidepressants have shown consistent efficacy. Data regarding antidepressant treatment of CFS is less copious and less uniformly positive, such that antidepressant use in CFS remains controversial. The current review aims to summarize available data related to antidepressants and other psychotropic agents in CFS to provide a platform for clinicians to make decisions in their treatment of this challenging syndrome. We identified relevant studies through a PubMed literature search with a combination of the following search terms: 'fatigue,' 'depression,' 'antidepressant,' 'etiology' (e.g., 'neurobiology,' 'neurotransmitter,' 'genetic'), 'diagnosis,' and 'treatment' (e.g., 'antidepressant' plus the specific name). In addition, studies were also identified via the reference sections of retrieved articles. The authors thoroughly reviewed major findings from the scanned literatures and eventually synthesized them, providing summary, interpretation, and future directions.

show abstract

“…• Other Treatments: The use of Essential Fatty Acids (Warren et al 1999), reduced form of oral nicotinamide adenine dinucleotide (Forsyth et al 1999) and Selegiline (Natelson et al 1998) has been of little value without any promising results. An experimental medication Ampligen, a synthetic nucleic acid Poly(I).Poly(C12U) is being studied for potential use in patients with CFS.…”

Section: Pharmacological Approachmentioning

confidence: 99%